Skip to main content
OpenTrials
Completed

NCT Number: NCT02050269

Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study

The objective of this study is to assess the feasibility of estimating the clearance of iohexol as an indirect measure of glomerular filtration rate in patients with unstable renal function in the intensive care unit through analysis of rich iohexol plasma kinetics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Circulatory Failure Pathologic Processes Pathological Conditions, Signs and Symptoms Shock

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospital La SOURCE, Orléans, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Patient admitted to intensive care for less than 12 hours
  • Acute circulatory failure
  • Patient carrying an arterial catheter
  • Informed consent obtained
  • Affiliated to social security system

Exclusion criteria

  • Administration of iohexol the week before intensive care admission
  • Administration of iohexol expected within 24 hours of study entry
  • Known history of cutaneous immediate or delayed allergic reaction to the injection of the product
  • Indication for albumin transfusion within 24 hours of potential inclusion in the study
  • Pregnancy or breastfeeding in progress
  • Patient under guardianship or judicial protection known at the time of inclusion
  • Withdrawal of consent
  • Administration of iohexol outside the study within 24 hours after administration of iohexol in the context of the study
  • Administration of intravenous albumin in the 24 hours following administration of iohexol in the context of the study

Treatment and study plan

Iohexol

Drug

Iohexol, 300 mg/mL

Primary outcomes

  1. Plasma clearance of iohexol

    Time frame: 24 hours

Secondary outcomes

  1. Plasma clearance of iohexol in patients developping or not acute kidney injury

    Time frame: 7 days

  2. Link between plasma iohexol clearance and kindney injury markers

    Time frame: 24 hours

  3. Link between injury and/or functional kidney dammage and subsequent acute kidney injury

    Time frame: 7 days

  4. Link between plasma iohexol clearance and urinary metabolomic markers

    Time frame: 24 hours

  5. Comparaison of plasma iohexol clearance measured with 3 and 6 vs. 9 kinetic points

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

University Hospital, Tours

Other

Registry information

Acronym: IoxRea

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Jan 30, 2014
Registry last updated
Dec 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.